Point72 Asia (Singapore) Pte. Ltd. Cardiff Oncology, Inc. Transaction History
Point72 Asia (Singapore) Pte. Ltd.
- $384 Billion
- Q1 2024
A detailed history of Point72 Asia (Singapore) Pte. Ltd. transactions in Cardiff Oncology, Inc. stock. As of the latest transaction made, Point72 Asia (Singapore) Pte. Ltd. holds 49,892 shares of CRDF stock, worth $103,775. This represents 0.07% of its overall portfolio holdings.
Number of Shares
49,892Holding current value
$103,775% of portfolio
0.07%Shares
1 transactions
Others Institutions Holding CRDF
# of Institutions
86Shares Held
8.48MCall Options Held
798KPut Options Held
39.2K-
Vanguard Group Inc Valley Forge, PA1.92MShares$4 Million0.0% of portfolio
-
Laurion Capital Management LP New York, NY929KShares$1.93 Million0.04% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny683KShares$1.42 Million0.0% of portfolio
-
Black Rock Inc. New York, NY677KShares$1.41 Million0.0% of portfolio
-
Mai Capital Management551KShares$1.15 Million0.03% of portfolio
About Cardiff Oncology, Inc.
- Ticker CRDF
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,334,900
- Market Cap $90.1M
- Description
- Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...